600079.SHG Humanwell Healthcare Group Co Ltd
- Market cap
- CNY 31.7B
- P/E
- 12.2x
- P/B
- 1.54x
- ROE
- 15.8%
- Dividend yield
- 3.33%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600079.SHG undervalued?
Graham number600079.SHG trades 8.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Humanwell Healthcare Group Co Ltd fundamental analysis
No fundamental analysis for Humanwell Healthcare Group Co Ltd yet.
Humanwell Healthcare Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use a…
Full company profileHumanwell Healthcare Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Humanwell Healthcare Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 12.3B | 15.4B | 18.6B | 21.8B | 20.7B | 20.5B | 22.3B | 24.5B | 25.4B | 24.0B | 24.5B |
| Gross Profit | 4.53B | 5.88B | 7.43B | 8.61B | 8.67B | 8.77B | 9.71B | 11.2B | 11.3B | 11.6B | 12.2B |
| Operating Income | 1.25B | 3.03B | -1.45B | 1.84B | 2.09B | 2.25B | 3.52B | 3.45B | 2.52B | 3.82B | 4.25B |
| EBITDA | 1.76B | 2.08B | 2.35B | 3.07B | 3.34B | 3.02B | 3.37B | 4.11B | 3.88B | 4.36B | 4.86B |
| Net Income | 832M | 2.07B | -2.36B | 843M | 1.01B | 1.32B | 2.48B | 2.13B | 1.33B | 1.86B | 3.22B |
| EPS | 0.63 | 1.53 | -1.81 | 0.62 | 0.73 | 0.82 | 1.54 | 1.31 | 0.82 | 1.14 | 1.97 |
| Balance Sheet | |||||||||||
| Total Assets | 26.4B | 36.3B | 36.2B | 36.1B | 32.4B | 35.4B | 36.0B | 36.2B | 36.5B | 36.7B | 37.7B |
| Total Liabilities | 14.4B | 19.4B | 21.7B | 21.8B | 19.4B | 19.8B | 18.1B | 16.1B | 15.8B | 14.7B | 14.1B |
| Shareholders' Equity | 10.0B | 13.5B | 10.8B | 10.2B | 10.6B | 12.9B | 15.0B | 17.0B | 17.6B | 18.9B | 20.4B |
| Cash & Short-term Investments | 3.21B | 4.35B | 4.18B | 4.32B | 6.20B | 6.10B | 6.12B | 5.04B | 4.95B | 4.14B | 4.75B |
| Total Debt | 7.88B | 10.2B | 11.7B | 12.1B | 13.4B | 13.0B | 10.2B | 9.95B | 8.41B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 526M | 38.2M | 603M | 2.04B | 1.99B | 2.18B | 2.44B | 1.97B | 2.16B | 2.52B | - |
| Capital Expenditure | 1.24B | 1.73B | 1.33B | 821M | 1.10B | 1.70B | 3.11B | 1.96B | 1.02B | 733M | 588M |
| Free Cash Flow | -718M | -1.70B | -732M | 1.22B | 891M | 476M | -672M | 8.93M | 1.14B | 1.79B | 1.79B |
| Ratios | |||||||||||
| ROE | 8.3% | 15.3% | -21.8% | 8.3% | 9.5% | 10.2% | 16.5% | 12.5% | 7.5% | 9.8% | 15.8% |
| ROA | 3.1% | 5.7% | -6.5% | 2.3% | 3.1% | 3.7% | 6.9% | 5.9% | 3.6% | 5.0% | 8.5% |
| Net Profit Margin | 6.8% | 13.4% | -12.7% | 3.9% | 4.9% | 6.4% | 11.1% | 8.7% | 5.2% | 7.7% | 13.1% |
| Debt to Equity | 0.78x | 0.76x | 1.08x | 1.19x | 1.26x | 1.00x | 0.68x | 0.58x | 0.48x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Humanwell Healthcare Group Co Ltd dividends
- Dividend yield
- 3.33%
- Forward dividend
- 0.48 CNY
- Payout ratio
- 56.9%
- Ex-dividend date
- Aug 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.06B | 0.65 | 56.9% |
| 2024 | CNY 1.27B | 0.78 | 95.5% |
| 2023 | CNY 588M | 0.36 | 27.5% |
| 2022 | CNY 245M | 0.15 | 9.9% |
| 2021 | CNY 161M | 0.10 | 12.2% |
| 2020 | CNY 67.0M | 0.05 | 6.7% |
| 2019 | CNY 87.2M | 0.06 | 10.3% |
| 2018 | CNY 1.04B | 0.80 | - |
| 2017 | CNY 566M | 0.42 | 27.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 22, 2015.
Who owns Humanwell Healthcare Group Co Ltd
- Insiders 40.73%
- Institutions 5.07%
- Public & others 54.20%
- Shares outstanding 1.63B
- Free float 1.17B
Humanwell Healthcare Group Co Ltd company profile
- Company name
- Humanwell Healthcare Group Co Ltd
- Ticker
- 600079.SHG
- ISIN
- CNE000000QW6
- Exchange
- Shanghai Stock Exchange
- Listed since
- May 22, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 17,153
- Fiscal year end
- December
- Address
- No. 666, Gaoxin Avenue, Wuhan, China, 430075
- Phone
- 86 27 8700371
- Website
- humanwell.com.cn
About Humanwell Healthcare Group Co Ltd
Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injection, a narcotic analgesic; remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery; and mifepristone preparations for pregnancy prevention or termination. It also provides zuka wood particles for colds; compound muniziqi granules to treat skin and gynecologicalconditions; urokinase injection for thromboembolic diseases; and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals. In addition, the company offers progesterone, estrogen, androgen, cortical hormone, and other API products; steroid hormone products; natural plant-based medicines; central nervous system drugs; animal medicine; narcotics; and Uyghur medicine products. Further, it is involved in the production of veterinary drugs, feed additive, medical devices, and agricultural products; technical development, exchange, and transfer; leasing of medical devices; conference, exhibition, inspection, and testing; property management; pharmaceutical contract manufacturing; cleaning, washing, and disinfection; warehousing and logistics; investment management and consulting services; and production of health foods. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1988 and is based in Wuhan, China.
Humanwell Healthcare Group Co Ltd management
6- Mr. Wentao DuGM & Financial Director · born 1968
- Mr. Qiang YinDeputy General Manager · born 1982
- Mr. Jun LiDeputy General Manager · born 1977
- Mr. Nanhong LiuDeputy GM & Board Secretary · born 1979
- Hua Qin HeAccounting Supervisor
- Mr. Chenggang ZhengDeputy General Manager · born 1972